GLP1R and cancer: Recently, Wang Yongxiang and colleagues provided the first evidence that activation of microglial glucagon-like peptide-1 receptor (GLP-1R) in the spinal cord specifically suppresses neuropathic pain, cancer pain, and diabetic hypersensitivity [20].